Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17426118 | 1.00 | PDE4B (0.55) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL4132542 | 1.00 | PDE4B (0.55) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL21335543 | 1.00 | PDE4B (0.55) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL28950424 | 1.00 | PDE4B (0.55) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL11916326 | 1.00 | PDE4B (0.55) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL23191704 | 1.00 | PDE4B (0.55) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL14801009 | 0.93 | SMN1; SMN2 (0.53) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL1468571 | 0.92 | USP30 (0.52) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL1468570 | 0.92 | USP30 (0.52) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL31520766 | 0.92 | PDE4B (0.53) | PDE4BSMN1; SMN2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | PFIZER INC. (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4038060-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11065249-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210100796-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-20210100798-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065249-B2 | Diacylglycerol acyl transferase 2 inhibitor | DGAT2, DGAT1, ACAT2 | PDE4B 817/4885SMN1; SMN2 4817/4885NPC1 192/4885 |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | PDE4B 1716/4885SMN1; SMN2 3818/4885NPC1 1582/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PDE4B 2918/4885SMN1; SMN2 2557/4885NPC1 4325/4885 |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | ACAT2, ACACB, ACACA | PDE4B 2308/4885SMN1; SMN2 4425/4885NPC1 162/4885 |
| US-20210100798-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | DGAT2, DGAT1, ACAT2 | PDE4B 827/4885SMN1; SMN2 4814/4885NPC1 184/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PDE4B 1716/4885SMN1; SMN2 3818/4885NPC1 1582/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PDE4B 2918/4885SMN1; SMN2 2557/4885NPC1 4325/4885 |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | PDE4B 3388/4885SMN1; SMN2 1336/4885NPC1 4665/4885 |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | DGAT2, DGAT1, ACAT2 | PDE4B 817/4885SMN1; SMN2 4817/4885NPC1 192/4885 |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | PDE4B 3668/4885SMN1; SMN2 1444/4885NPC1 4431/4885 |
| US-20210100796-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | DGAT2, DGAT1, ACAT2 | PDE4B 817/4885SMN1; SMN2 4817/4885NPC1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.